While larger prospective studies are needed to validate these findings, our results suggest that [68Ga]Ga-PSMA-11 PET/CT could play a crucial role in improving the management and outcomes of patients with recurrent prostate cancer after focal therapy. The gene discussed is FOLH1; the disease is prostate cancer.